Advanced search
Add to list

Colonization of voice prostheses by albicans and non-albicans Candida species

(2002) LARYNGOSCOPE. 112(4). p.708-712
Author
Organization
Abstract
Objectives: The purposes of the study were to assess the colonization of tracheoesophageal voice prostheses by albicans and non-albicans Candida species and to determine their susceptibility for three antimycotics that are frequently used for prophylaxis or treatment of oral candidiasis (i.e., miconazole, fluconazole, and nystatin). Study Design: In total, 101 patients, corresponding to 170 voice prostheses, were monitored over a period of 28 months. Methods. An enzymatic two-step method was used for differentiation and presumptive identification of Candida species colonizing the voice prostheses. The identity of the isolates was confirmed by the germ-tube test, morphological appearance on corn-meal agar with 0.5%, Tween 80, sugar assimilation tests, and appearance on CHROMagar Candida (CHROMagar Co., Paris), Albicans ID (BioMerieux Vitek, Hazelwood, MO), and Fluoroplate Candida (Merck, Darmstadt, Germany). Susceptibility testing for miconazole, fluconazole, and nystatin was performed according to the microdilution method of the National Committee for Clinical Laboratory Standards. Results: The predominant species isolated were Candida albicans (41.4%), Candida glabrata (33.1%), Candida krusei (15.9%), and Candida tropicalis (5.3%). A broad range of minimal inhibitory concentrations of the isolates was observed for miconazole and fluconazole. In contrast, minimal inhibitory concentration values for nystatin were narrowly distributed around 4 mug/mL for all isolates, suggesting uniform sensitivity. Conclusion: Our data on the prevalence and susceptibility of yeast isolates will contribute to a rational choice of an antimycotic for prophylaxis of the early deterioration and leakage of tracheoesophageal voice prostheses.
Keywords
GLABRATA, DETERIORATION, Candida, susceptibility, colonization, voice prostheses, BACTERIA, EPIDEMIOLOGY, SILICONE-RUBBER

Citation

Please use this url to cite or link to this publication:

MLA
Bauters, Tieneke, et al. “Colonization of Voice Prostheses by Albicans and Non-Albicans Candida Species.” LARYNGOSCOPE, vol. 112, no. 4, 2002, pp. 708–12, doi:10.1097/00005537-200204000-00021.
APA
Bauters, T., Moerman, M., Vermeersch, H., & Nelis, H. (2002). Colonization of voice prostheses by albicans and non-albicans Candida species. LARYNGOSCOPE, 112(4), 708–712. https://doi.org/10.1097/00005537-200204000-00021
Chicago author-date
Bauters, Tieneke, Mieke Moerman, Hubert Vermeersch, and Hans Nelis. 2002. “Colonization of Voice Prostheses by Albicans and Non-Albicans Candida Species.” LARYNGOSCOPE 112 (4): 708–12. https://doi.org/10.1097/00005537-200204000-00021.
Chicago author-date (all authors)
Bauters, Tieneke, Mieke Moerman, Hubert Vermeersch, and Hans Nelis. 2002. “Colonization of Voice Prostheses by Albicans and Non-Albicans Candida Species.” LARYNGOSCOPE 112 (4): 708–712. doi:10.1097/00005537-200204000-00021.
Vancouver
1.
Bauters T, Moerman M, Vermeersch H, Nelis H. Colonization of voice prostheses by albicans and non-albicans Candida species. LARYNGOSCOPE. 2002;112(4):708–12.
IEEE
[1]
T. Bauters, M. Moerman, H. Vermeersch, and H. Nelis, “Colonization of voice prostheses by albicans and non-albicans Candida species,” LARYNGOSCOPE, vol. 112, no. 4, pp. 708–712, 2002.
@article{165493,
  abstract     = {{Objectives: The purposes of the study were to assess the colonization of tracheoesophageal voice prostheses by albicans and non-albicans Candida species and to determine their susceptibility for three antimycotics that are frequently used for prophylaxis or treatment of oral candidiasis (i.e., miconazole, fluconazole, and nystatin). Study Design: In total, 101 patients, corresponding to 170 voice prostheses, were monitored over a period of 28 months. Methods. An enzymatic two-step method was used for differentiation and presumptive identification of Candida species colonizing the voice prostheses. The identity of the isolates was confirmed by the germ-tube test, morphological appearance on corn-meal agar with 0.5%, Tween 80, sugar assimilation tests, and appearance on CHROMagar Candida (CHROMagar Co., Paris), Albicans ID (BioMerieux Vitek, Hazelwood, MO), and Fluoroplate Candida (Merck, Darmstadt, Germany). Susceptibility testing for miconazole, fluconazole, and nystatin was performed according to the microdilution method of the National Committee for Clinical Laboratory Standards. Results: The predominant species isolated were Candida albicans (41.4%), Candida glabrata (33.1%), Candida krusei (15.9%), and Candida tropicalis (5.3%). A broad range of minimal inhibitory concentrations of the isolates was observed for miconazole and fluconazole. In contrast, minimal inhibitory concentration values for nystatin were narrowly distributed around 4 mug/mL for all isolates, suggesting uniform sensitivity. Conclusion: Our data on the prevalence and susceptibility of yeast isolates will contribute to a rational choice of an antimycotic for prophylaxis of the early deterioration and leakage of tracheoesophageal voice prostheses.}},
  author       = {{Bauters, Tieneke and Moerman, Mieke and Vermeersch, Hubert and Nelis, Hans}},
  issn         = {{0023-852X}},
  journal      = {{LARYNGOSCOPE}},
  keywords     = {{GLABRATA,DETERIORATION,Candida,susceptibility,colonization,voice prostheses,BACTERIA,EPIDEMIOLOGY,SILICONE-RUBBER}},
  language     = {{eng}},
  number       = {{4}},
  pages        = {{708--712}},
  title        = {{Colonization of voice prostheses by albicans and non-albicans Candida species}},
  url          = {{http://doi.org/10.1097/00005537-200204000-00021}},
  volume       = {{112}},
  year         = {{2002}},
}

Altmetric
View in Altmetric
Web of Science
Times cited: